Shields Matthew 4

What Happened
Matthew Shields, EVP, Global Operations of Teva Pharmaceutical Industries (TEVA), had 17,295 restricted share units vest and convert into ordinary shares on March 5, 2026, and sold 17,295 shares in an open‑market transaction for total proceeds of $547,705 (weighted average price $31.67). A related derivative disposition of shares for tax withholding was reported at $0 per share. The sale was executed under a Rule 10b5‑1 trading plan.

Key Details

• Transaction date: March 5, 2026. Form 4 filed March 9, 2026 (within the usual two-business-day deadline).
• Open-market sale: 17,295 shares at a weighted average price of $31.67; proceeds $547,705. Reported sale prices ranged $31.26–$32.34.
• Derivative/conversion: 17,295 RSUs converted to shares (reported as exercise/conversion). A separate derivative disposition of 17,295 shares at $0 was reported for tax withholding.
• Plan/footnotes: Transactions effected pursuant to a 10b5‑1 plan adopted Nov 10, 2025. RSUs were originally granted Mar 5, 2025 with vesting schedule (17,295 vesting each Mar 5 in 2026–2028; 17,297 in 2029).
• Shares owned after the transactions: not disclosed in the provided filing.
• ADS note: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share).

Context
This was a vesting/conversion of restricted share units followed by an immediate sale (common for settlement and tax obligations). The filing is factual: it does not indicate intent or sentiment. Purchases tend to be more informative about insider conviction; this is a routine sale tied to RSU vesting and executed under a preexisting 10b5‑1 plan.